NASDAQ:OPGN - OpGen Stock Price, News, & Analysis

$0.40
-0.02 (-4.76 %)
(As of 06/18/2019 02:36 PM ET)
Today's Range
$0.39
Now: $0.40
$0.40
50-Day Range
$0.41
MA: $0.46
$0.5324
52-Week Range
$0.36
Now: $0.40
$2.41
Volume9,051 shs
Average Volume952,636 shs
Market Capitalization$7.06 million
P/E RatioN/A
Dividend YieldN/A
Beta0.93
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPGN
CUSIPN/A
Phone240-813-1260

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.95 million
Book Value$0.38 per share

Profitability

Net Income$-13,370,000.00
Net Margins-454.23%

Miscellaneous

Employees44
Market Cap$7.06 million
Next Earnings Date8/1/2019 (Estimated)
OptionableNot Optionable

Receive OPGN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter.

OpGen (NASDAQ:OPGN) Frequently Asked Questions

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

When did OpGen's stock split? How did OpGen's stock split work?

OpGen's stock reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

How were OpGen's earnings last quarter?

OpGen Inc (NASDAQ:OPGN) issued its quarterly earnings results on Thursday, August, 2nd. The medical research company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.03. The medical research company had revenue of $0.79 million for the quarter, compared to analyst estimates of $0.79 million. OpGen had a negative return on equity of 313.92% and a negative net margin of 454.23%. View OpGen's Earnings History.

When is OpGen's next earnings date?

OpGen is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for OpGen.

What price target have analysts set for OPGN?

2 Wall Street analysts have issued 1-year price objectives for OpGen's stock. Their predictions range from $1.50 to $2.30. On average, they anticipate OpGen's share price to reach $1.90 in the next twelve months. This suggests a possible upside of 375.0% from the stock's current price. View Analyst Price Targets for OpGen.

What is the consensus analysts' recommendation for OpGen?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OpGen.

What are Wall Street analysts saying about OpGen stock?

Here are some recent quotes from research analysts about OpGen stock:
  • 1. According to Zacks Investment Research, "OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. " (6/18/2019)
  • 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $71M. This includes a discounted cash flow analysis based enterprise value of $72M for the QuickFISH and Acuitas products, with a 15% discount rate and 2% terminal growth rate, excluding $1M debt." (5/19/2019)

Has OpGen been receiving favorable news coverage?

Media stories about OPGN stock have been trending neutral recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OpGen earned a daily sentiment score of 0.1 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for OpGen.

Are investors shorting OpGen?

OpGen saw a drop in short interest in May. As of May 15th, there was short interest totalling 148,100 shares, a drop of 23.5% from the April 15th total of 193,700 shares. Based on an average daily volume of 295,600 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.9% of the company's shares are sold short. View OpGen's Current Options Chain.

Who are some of OpGen's key competitors?

What other stocks do shareholders of OpGen own?

Who are OpGen's key executives?

OpGen's management team includes the folowing people:
  • Mr. Evan Jones, Chairman & CEO (Age 62)
  • Mr. Timothy C. Dec, CFO & Corp. Sec. (Age 60)
  • Mr. Vadim Sapiro, Chief Information Officer (Age 48)
  • Mr. Michael Farmer, VP of Marketing
  • Dr. G. Terrance Walker Ph.D., Sr. VP of R&D (Age 60)

When did OpGen IPO?

(OPGN) raised $17 million in an initial public offering on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

Who are OpGen's major shareholders?

OpGen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (1.34%). Company insiders that own OpGen stock include Evan/ Fa Jones, Jven Capital, Llc and Timothy C Dec. View Institutional Ownership Trends for OpGen.

Which institutional investors are buying OpGen stock?

OPGN stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought OpGen stock in the last two years include Evan/ Fa Jones, Jven Capital, Llc and Timothy C Dec. View Insider Buying and Selling for OpGen.

How do I buy shares of OpGen?

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OpGen's stock price today?

One share of OPGN stock can currently be purchased for approximately $0.40.

How big of a company is OpGen?

OpGen has a market capitalization of $7.06 million and generates $2.95 million in revenue each year. The medical research company earns $-13,370,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. OpGen employs 44 workers across the globe.View Additional Information About OpGen.

What is OpGen's official website?

The official website for OpGen is http://www.opgen.com/.

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]


MarketBeat Community Rating for OpGen (NASDAQ OPGN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  221 (Vote Outperform)
Underperform Votes:  234 (Vote Underperform)
Total Votes:  455
MarketBeat's community ratings are surveys of what our community members think about OpGen and other stocks. Vote "Outperform" if you believe OPGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2019 by MarketBeat.com Staff

Featured Article: Back-End Load

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel